New directions in the management of advanced pancreatic cancer: a review

@article{RochaLima2008NewDI,
  title={New directions in the management of advanced pancreatic cancer: a review},
  author={C. Rocha-Lima},
  journal={Anti-Cancer Drugs},
  year={2008},
  volume={19},
  pages={435-446}
}
  • C. Rocha-Lima
  • Published 2008
  • Medicine
  • Anti-Cancer Drugs
  • Complete surgical resection is the only potentially curative option for pancreatic cancer. However, most patients have advanced/metastatic disease at the time of diagnosis, or will relapse after surgery. Systemic chemotherapy is only palliative. Gemcitabine-based therapy is an acceptable standard for unresectable locally advanced/metastatic pancreatic cancer, but average median survival is only 6 months. The addition of other chemotherapies (including other antimetabolites, platinum, and… CONTINUE READING
    38 Citations
    Pancreatic Cancer Treatment
    • 7
    • PDF
    Emerging drugs in the treatment of pancreatic cancer
    • 21
    Management of advanced pancreatic cancer
    • 4
    The role of radiotherapy in locally advanced pancreatic carcinoma
    • 34
    Challenges in developing targeted therapy for pancreatic adenocarcinoma
    • 3
    Current evidence for histone deacetylase inhibitors in pancreatic cancer.
    • 30

    References

    SHOWING 1-10 OF 112 REFERENCES
    Combined modality therapy for pancreatic cancer.
    • 32
    Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
    • 414
    Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    • 3,321
    • PDF
    Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
    • 5,002
    • PDF
    Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
    • 453
    Phase II trial of capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma.
    • 1
    Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
    • H. Kindler, G. Friberg, +8 authors E. Vokes
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2005
    • 445
    Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
    • 54